Nureca
Nureca Q2 Results 2026 (FY27) statement: Revenue & Margins
Q2 FY27 results statement: what the company reported on revenue, margins and capex.
Nureca Q2 FY27 key numbers
- Revenue
- Year-on-year growth in revenue from operations: approximately 55% increase (585.99 vs 378.41 million standalone).
As stated in Nureca's Q2 FY27 results statement · published 22 Oct 2026. Reported figures, not investment advice.
Based on Nureca's Q2 FY27 results statement. The company has not published an earnings-call transcript for this quarter, so figures here are what the results statement reports, not management guidance.
The short version
Revenue from operations for the quarter ended 30 September 2026: - Standalone: Rs. - Profit after tax (PAT) for the standalone quarter ending September 30, 2026, is Rs.
From Nureca's Q2 FY27 earnings-call transcript · updated 22 Oct 2026.
Revenue & Sales Performance
- Revenue from operations for the quarter ended 30 September 2026:
- Standalone: Rs. 585.99 million
- Consolidated: Rs. 585.26 million
- Year-on-year comparison (quarter ended 30 September 2025):
- Standalone: Rs. 378.41 million
2 more points from Nureca's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Nureca said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
2 more points from Nureca's call on capex
Create a free account to keep reading this call
Fundraising & Capital Structure
See what Nureca said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Nureca said on order book & pipeline — free account, 30 seconds.
Nureca — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹59 Cr, net profit ₹4 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Nureca Ltd's management said in earlier quarters
Others in Healthcare Equipment & Supplies this season
- Galaxy Medicare (Q2 FY27)
Revenue from Operations (₹ Mn): . Key investor presentation takeaways from Galaxy Medicare's Q2 FY27 investor presentation — and how it ranks against sector pee
Potential multibaggers · Q2 FY27
This quarter's potential multibaggers
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Nureca and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Nureca Q2 FY27 results?
Revenue from operations for the quarter ended 30 September 2026: - Standalone: Rs. - Profit after tax (PAT) for the standalone quarter ending September 30, 2026, is Rs.
What is Nureca share price analysis?
Nureca currently shows a neutral. The stock trades at a P/E of 72.3 with a market cap of ₹314 Cr. Investors should review the full earnings analysis for detailed insights.
Is Nureca planning capital expenditure?
The results statement outlines the following capex and capacity expansion initiatives: - Capital Work in Progress: - Standalone: Rs.
Keep Nureca on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's results statement. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.